TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05257642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REThink Game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REThink Game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REThink Game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
Study: NCT06066580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten
Description: Sevasemten is administered orally once per day
Study: NCT04100564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device
Description: Initial advanced airway management with a supraglottic device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard airway management
Description: Initial advanced airway management with standard care method
Study: NCT06350071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: Kangaroo care will be applied so that the infant and mother will have skin-to-skin contact, and heel blood will be taken.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Heel blood will be taken while the infant was swaddled in the maternal holding.
Study: NCT05073679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: 25mg x 3 days then 50mg a day thereafter

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Methylcellulose and gelatin capsule only
Study: NCT04983303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICK-B group
Description: These interventions will distract the child during venipuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICK-B group
Description: These interventions will distract the child during venipuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICK-B group
Description: These interventions will distract the child during venipuncture
Study: NCT05052307

Intervention type: DRUG
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: DRUG
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: DRUG
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: DRUG
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: DRUG
Intervention: CoronaVac COVID-19 vaccine
Description: CoronaVac COVID-19 vaccine

Intervention type: DRUG
Intervention: CoronaVac COVID-19 vaccine
Description: CoronaVac COVID-19 vaccine

Intervention type: DRUG
Intervention: ChAdOx1 nCoV-19 Covid-19 Vaccine
Description: ChAdOx1 nCoV-19 Covid-19 Vaccine
Study: NCT06671288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon-blowing exercises with abdominal & lumbar core muscle activation position.
Description: Patients in this group will recieve Balloon-blowing exercises with abdominal and lumbar core muscles activation position Total 4 weeks protocol will be followed in which 3 sessions per week will be supervised by physical therapist.~FREQUENCY: 3 times a week, INTENSITY : Moderate, TIME: 4 sets of balloon-blowing with 1 min rest (30 mins) TYPE: Balloon-blowing with abdominal \& lumbar core muscle activation position, DURATION : 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercise
Description: Participants in this group will only be receiving diaphragmatic breathing exercise for 4 weeks. FREQUENCY: 3 times a week , INTENSITY: Moderate, TIME: 4 sets of diaphragmatic breathing with 1 min rest, TYPE: Diaphragmatic breathing, DURATION: 4 weeks
Study: NCT06672328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training with Action Observation Therapy
Description: AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training without Action Observation Therapy
Description: Cerebral Palsy patients will receive balance and mobility training without action observation in various stances of sitting, standing and turning.~Activities are fun based and include reaching for objects, tower building and taking turns in different positions.
Study: NCT06672562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Enhancement and Cognitive Therapy
Description: NECT-Y consists of 14 90-minute sessions over the course of 14 weeks. The intervention combines psychoeducation, cognitive therapy, narrative therapy, goal-setting and peer support. Each group meeting includes educational materials, reflections, and active exercises that participants are guided through to personalize the content to their experiences. Participants will be provided with a workbook which allows them to follow the activities easier.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard usual care. No study-specific care, but participants will be provided with information on community resources and support, and will also be encouraged to speak to their clinician if they are interested in learning about other services.
Study: NCT06671444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Single oral dose, 20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Single oral dose, 20 mg tablet
Study: NCT06673030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using Kaleidoscope glasses during pulpotomy procedures
Description: Kaleidoscope is an instrument that shows an infinite number of fascinating geometric shapes in the form of a flower, repeating and reflecting images of coloured goggle fragments in the front section in a prism mirroring the inner surface.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Play-Doh Doctor Drill 'n Fill toy set
Description: Consists of a plastic human head with slots into which Play-doh molded teeth can be inserted. A battery operated toy drill is used to drill into and clean the black, cavitated tooth model and filled with white Play-Doh compound to simulate cavity preparation and restoration using tooth colored cement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (Tell-Show-Do)
Description: In which Tell-Show-Do technique was done in three stages:~* Tell: The dental procedures were explained to the children using language and expressions appropriate for their age.~* Show: This began with showing the child the instruments and the topical anesthetic gel, high-speed handpiece and explaining the purpose of using the handpiece. and how the water removed using the suction device.~* Do: Performing the dental procedure immediately.
Study: NCT06672835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eBASIS
Description: eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: eAttention Control
Description: eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
Study: NCT06673134

Intervention type: DRUG
Intervention: enteral nutrition
Description: exclusive enteral nutrition therapy or Partial enteral nutrition

Intervention type: DRUG
Intervention: enteral nutrition
Description: exclusive enteral nutrition therapy or Partial enteral nutrition
Study: NCT05495061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1012600 ophthalmic solution 0.002%
Description: 1 drop STN1012600 ophthalmic solution 0.002% once daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Description: 1 drop Latanoprost ophthalmic solution 0.005% once daily for 3 months
Study: NCT06673134

Intervention type: DRUG
Intervention: enteral nutrition
Description: exclusive enteral nutrition therapy or Partial enteral nutrition

Intervention type: DRUG
Intervention: enteral nutrition
Description: exclusive enteral nutrition therapy or Partial enteral nutrition

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc

Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc

Intervention type: DRUG
Intervention: biological agents
Description: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc

Intervention type: DRUG
Intervention: biological agents
Description: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc

Intervention type: DRUG
Intervention: biological agents
Description: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
Study: NCT06083948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenalin
Description: Infusion of noradrenaline during anesthesia and surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Infusion of phenylephrine during anesthesia and surgery
Study: NCT06247397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Added high-flow oxygen therapy
Description: Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care with low-flow oxygen therapy in accordance with clinical routine.
Study: NCT04447989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil citrate injection or powder for suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil citrate injection or powder for suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil citrate injection or powder for suspension
Study: NCT06673134

Intervention type: DRUG
Intervention: biological agents
Description: Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
Study: NCT04447989

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dextrose 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dextrose 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dextrose 5%
Study: NCT05443347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Supervised aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Biweekly newsletter
Study: NCT05594992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week
Study: NCT05297903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb20717
Description: 10mg/kg IV
Study: NCT06462443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE for Physicians Program
Description: RISE for Physicians Program. Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
Study: NCT05052307

Intervention type: DRUG
Intervention: ChAdOx1 nCoV-19 Covid-19 Vaccine
Description: ChAdOx1 nCoV-19 Covid-19 Vaccine
Study: NCT05115474

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo MRI imaging with and without contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo MRI imaging with and without contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Participants will undergo MRI imaging with and without contrast.
Study: NCT05775094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
Study: NCT06644261

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine injection
Description: Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine injection
Description: Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks
Study: NCT05039229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nozzles (NZ)
Description: Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning of surfaces (CS)
Description: Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
Study: NCT05417789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Emactuzumab administered once every 2 weeks (q2w)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered once every 2 weeks (q2w)
Study: NCT05644249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy
Description: Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
Study: NCT04869553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management pain with distraction methods ABC
Description: Every patient will receive :~* The usual pain management of their ward (Treatment A),~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management pain with distraction methods BCA
Description: Every patient will receive :~* The usual pain management of their ward with a hypnosis session (Treatment B)~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management pain with distraction methods CAB
Description: Every patient will receive :~* The usual pain management of their ward with a virtual reality session (Treatment C)~* The usual pain management of their ward (Treatment A)~* The usual pain management of their ward with a hypnosis session (Treatment B)
Study: NCT05052307

Intervention type: DRUG
Intervention: Ad26.COV2.S COVID-19 Vaccine
Description: Ad26.COV2.S COVID-19 Vaccine

Intervention type: DRUG
Intervention: Ad26.COV2.S COVID-19 Vaccine
Description: Ad26.COV2.S COVID-19 Vaccine
Study: NCT05136651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship
Description: The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
Study: NCT05854264

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: standard enteral nutrition
Description: standard enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: specialized nutrition
Description: specialized enteral nutrition. The calories (25 kcal/kg/die) and protein (1.2 g/kg/die) target will be progressively reached in the first week of ICU stay.
Study: NCT06479083

Intervention type: OTHER
Group type: OTHER
Intervention: New Intervention form including
Description: The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: The standard treatment which all compulsory insured patients get.
Study: NCT06673134

Intervention type: DRUG
Intervention: Glucocorticoids
Description: Glucocorticoids treatments are given

Intervention type: DRUG
Intervention: Glucocorticoids
Description: Glucocorticoids treatments are given

Intervention type: DRUG
Intervention: Glucocorticoids
Description: Glucocorticoids treatments are given
Study: NCT06278298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: CDT and different dose of shockwave

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave
Description: CDT and different dose of shockwave

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CDT
Description: CDT
Study: NCT06673134

Intervention type: OTHER
Intervention: fecal microbiota transplantation
Description: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc

Intervention type: OTHER
Intervention: fecal microbiota transplantation
Description: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc

Intervention type: OTHER
Intervention: fecal microbiota transplantation
Description: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc

Intervention type: OTHER
Intervention: fecal microbiota transplantation
Description: Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc
Study: NCT06672952

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
Description: The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
Description: The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
Study: NCT06672016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal system containing progestin
Description: MR-130A-01 transdermal system, patch to be used for female contraception
Study: NCT06671132

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain
Description: CBOT device with beta-caryophyllene

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)
Description: CBOT device administering continuous olfactoy stimuli with no BCP
Study: NCT06673329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab 210 mg subcutaneous injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment